Update on the Treatment of Overactive Bladder
Leslie Wooldridge, NP

Thursday June 25 2009
6:30PM Refreshments
7:00PM Dinner & Lecture
Cityscape
125 S Kalamazoo Mall # 103, Kalamazoo, MI
Above Union Cabaret—Second Floor
Parking available in ramp behind Union

View Larger Map

2 CEU
Please Rsvp To William Urfer At (269)381-2256 or william@swmpa.org by Monday May 22th.

Graciously sponsored by Maria Szwathowski of Astellas

Allergy Treatment Update 2009
Seshagiri Dandamundi, MD

Thursday May 28, 2009
6:30PM Refreshments
7:00PM Dinner & Lecture
Cityscape
125 S Kalamazoo Mall # 103, Kalamazoo, MI
Above Union Cabaret—Second Floor
Parking available in ramp behind Union

View Larger Map

2 CEU
Please Rsvp To William Urfer At (269)381-2256 or william@swmpa.org by Tuesday May 26th.

Graciously Sponsored by John Muloz Of UCB Pharma

FDA remains committed to taking enforcement actions against unapproved drugs in an effort to ensure that drugs used by patients are safe and effective, while at the same time ensuring that such actions do not impose an undue burden on patients. Currently, there are no approved morphine sulfate oral solution 20 mg/ml products being marketed in the U.S. FDA has heard from the pain management community that the impending market removal of unapproved morphine sulfate oral solution 20 mg/ml products announced in the Warning Letters would impose unacceptable hardship on palliative care patients, their families and caregivers. In light of this information, FDA will extend the enforcement discretion set forth in the Warning Letters to ensure that palliative care patients have access to morphine sulfate oral solution 20 mg/ml. The period of enforcement discretion will be extended until 180 days after any firm receives approval for a morphine sulfate oral solution 20 mg/ml product or if FDA determines that alternative medications become available for the palliative care patient.

More information…

Treatment Of Insomnia

Presented by
Nella Bieszk, Pharm D.

Thursday March 19, 2009
6:30pm Refreshments
7:00pm Dinner And Lecture

Bravo restaurant
across from the Kalamazoo-Battle Creek International Airport

View Larger Map

2 CEU Pending

RSVP to William Urfer At (269)381-2256 william@swmpa.org by Monday March 16th.

Graciously sponsored by Josh Fuller Of Sanofi-Aventis U.S.

At its 2009 session, the House of Delegates presented the Southwest Michigan Pharmacists Association with its Local Association Achievement award. SWMPA joined the Capital Area, Jackson Area, North Michigan, Wayne County, and Western Michigan pharmacist associations, who were also given this award. Continuing Education & Program Director William Urfer accepted the award on behalf of the association.

SWMPA would like to thank the Michigan Pharmacists Association, all MPA members, all of our continuing education sponsors, and especially those MPA members who participate in our local activities. Your support, along with all members of the MPA, make our organization possible.

SWMPA would also like to take this time to again ask for your participation in the Michigan Pharmacists Association. Not only is this a great way to connect with your peers and colleagues in the profession, your membership also makes you a true part of our organization and ensures that SWMPA remains a strong, active chapter of the MPA and within our community.

Thank you all very much.

MPA Convention Website

Join MPA

Getting started with Google Reader

Approaches In The Management Of Post-Menopausal Osteoporosis

Andrew Sulich, Md
Internal Medicine, Rheumatology
St Clair Shores, MI

Thursday, March 5, 2009

Please note the earlier time than usual.
6:00pm Refreshments
6:30pm Dinner And Lecture

Webster’s Sol Cafe
Raddison
100 West Michigan Ave
343-4444

View Larger Map

2 CEU Pending.

RSVP to William Urfer (269)381-2256 or william@swmpa.org
By March 4, 2009

Graciously Sponsored by Julie Helm Of Hoffmann-La Roche

Be sure to register for the MPA’s Annual Convention & Exposition by Feb. 5 to take advantage of discounted rates. Check out the latest educational programming for the convention online.

View the full schedule here.

The Role Of Omega-3-Acid Ethyl Esters In Treatment Of Adult Patients With Very High Triglycerides (≥500mg/Dcl)

We regret to inform you that this event is full.

Thursday, February 19th, 2009
Tim Hill, Pharm. D.
6:30PM Refreshments
7:00PM Dinner/Lecture
The Radisson
100 W Michigan
(free parking in ramp)

View Larger Map

Graciously sponsored by Daniel Aaberg of GlaxoSmithKline

Pfizer to buy Wyeth for $68 billion, cut jobs
Source: Associated Press/AP Online
Publication date: 2009-01-26

NEW YORK - Pfizer Inc. is buying rival drugmaker Wyeth in a $68 billion cash-and-stock deal that will increase its revenue by 50 percent, solidfy its No. 1 rank in the troubled industry and transform it from a pure pharmaceutical company into a broadly diversified health care giant.
At the same time, Pfizer announced cost cuts that include slashing more than 8,000 jobs.

The deal comes as Pfizer’s profit takes a brutal hit from a $2.3 billion legal settlement over allegations it marketed certain products for indications they have not been approved. The New York-based company is also cutting 10 percent of its work force of 83,400, slashing its dividend, and reducing the number of manufacturing sites.

Early Monday, Pfizer, the maker of cholesterol treatment Lipitor, the world’s top-selling drug, and impotence pill Viagra, said it will pay $50.19 per share under for Wyeth, valuing Madison, N.J.-based Wyeth at a 14.7 percent premium to the company’s closing price of $43.74 Friday.

Both companies’ boards of directors approved the deal but Wyeth shareholders must do so, antitrust regulators must review the deal and a consortium of banks lending the companies $22.5 billion must complete the financing.

Pfizer has been under pressure from Wall Street to make a bold move as it faces what is referred to as a patent cliff in the coming years. As key drugs lose patent protection they will face generic competition and declining sales. Lipitor is expected to face generic competition starting in November 2011. It brings in nearly $13 billion per year for the company.

Acquiring Wyeth helps Pfizer diversify and become less-dependent on individual drugs - Lipitor now provides about one-fourth of all Pfizer revenue - while adding strength in biotech drugs, vaccines and consumer products. Wyeth makes the world’s top-selling vaccines, Prevnar for meningitis and pneumococcal disease, and co-markets with Amgen Inc. the world’s No. 1 biotech drug, Enbrel for rheumatoid arthritis.

“The combination of Pfizer and Wyeth provides a powerful opportunity to transform our industry,” Pfizer Chairman and Chief Executive Jeffery B. Kindler said in a statement. “It will produce the world’s premier biopharmaceutical company whose distinct blend of diversification, flexibility, and scale positions it for success in a dynamic global health care environment.”

Together, and the two companies will have 17 different products with annual sales of $1 billion or more, including top antidepressant Effexor, Lyrica for fibromyalgia and nerve pain, Detrol for overactive bladder and blood pressure drug Norvasc.

Shortly after announcing the Wyeth deal, Pfizer said fourth-quarter profit plunged on a charge to settle investigations into off-label marketing practices. The company earned $268 million, or 4 cents per share, compared with profit of $2.72 billion, or 40 cents per share, a year prior. Revenue fell 4 percent to $12.35 billion from $12.87 billion.

Excluding about $2.3 billion in legal charges, the company says profit rose to 65 cents per share.

Analysts polled by Thomson Reuters expected profit of 59 cents per share on revenue of $12.54 billion.

Looking ahead, New York-based Pfizer expects earnings per share between $1.85 and $1.95 in 2009, below forecasts for $2.49.

Burnout, Stress, and Fatigue

Dr. Michael Howard

Fri. Jan 23. 2009
8:30am to 3:30pm
Fetzer Center WMU
1903 W. Michigan ave
Kalamazoo, michigan

6 CEU

Rsvp to 1-800-937-6878 (Pack your own lunch)
For more information call William Urfer at (269)381-2256

Tution: $84.00

Sponored by INR

Maria Szatkowski has lost a product bag at the last Friday night meeting. It has some product in it that she has to inventory. If you got the bag by accident could you please phone her at (269)598-8563.

Ivax (now owned by Teva Pharmaceuticals) have received FDA approval to market their generic version of AstraZeneca’s Pulmicort Respules in 0.25mg/ml and 0.5mg/ml strengths. More details here.

PITTSBURGH, Nov. 17 /PRNewswire-FirstCall/ — Mylan Inc. (NYSE: MYL) today announced that its subsidiary, Mylan Pharmaceuticals Inc., received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride (HCl) Extended-release (ER) Capsules, 37.5 mg (base), 75 mg (base) and 150 mg (base).

Venlafaxine HCl ER Capsules, indicated for the treatment of major depressive disorder and generalized anxiety disorder, are the generic version of Wyeth Pharmaceutical Inc.’s Effexor XR(R) Capsules. This product had annual U.S. sales of approximately $3 billion for the 12 months ending Sept. 30, 2008, for the noted strengths, according to IMS Health.

Currently, Mylan has 112 ANDAs pending FDA approval, 23 of which are potential first-to-file opportunities.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry’s broadest — and highest quality — product portfolios, supported by a robust product pipeline; owns a controlling interest in the world’s third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc. 11/17/2008 CONTACT: Media: Michael Laffin, +1-724-514-1968, or Investors: Dan Crookshank, +1-724-514-1813, both of Mylan Inc. /Web site: http://www.mylan.com (MYL)

Osteoporosis Therapy Updates
Formulary Updates
Trivia & Prizes!

Friday, November 21, 2008
6:30PM Refreshments
7:00PM Hors d’oeuvres and Party
Limited to the first 30 reservations due to limited seating.
If you are attending Thursday’s dinner, please consider others who might instead be able to attend tonight.
RSVP to William Urfer (269)381-2256 or william@swmpa.org by November 17.

Or use Google Calendar

CEU Pending.

Food Dance Cafe
401 E Michigan
Kalamazoo, MI 49007

View Larger Map

Graciously sponsored by Maria Szatkowski of Sanofi-Aventis